Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late. Apr 21, 2016
The Market – On Its Head
Let’s discuss what’s been working and what’s not been working in today’s market. Jan 29, 2016
Alerts: High-grading! GILD-->JNJ; EBAY-->FB
We’re “high-grading” the Best Ideas Newsletter portfolio. Jan 25, 2016
What’s Working in Today’s Market?
Let’s take a look at the major sectors to see where assets are flocking to and away from so far in 2016. We’ll talk about recent news, and several equities we’re paying particularly close attention to for addition to the newsletter portfolios. Dec 18, 2015
Analysis: The Best Ideas Portfolio
The Best Ideas Newsletter portfolio is one of the most followed newsletter portfolios among our membership. In the spirit of transparency, let’s examine the portfolio’s returns from a variety of different perspectives. The Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Results are hypothetical and do not represent actual trading. Past results are not a guarantee of future performance. Dec 6, 2015
Leading Investors to Water…
…did they drink? Let’s examine the performance of Valuentum’s best ideas in 2015. Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer… Sep 1, 2015
Batten Down the Hatches – Another US Market Crash Probable
The aftermath of China’s equity market collapse and the Dow’s crash last week will have material spillover effects. Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer... Jul 23, 2015
Guide to Second Quarter Earnings; Big Pharma Experiencing Earnings Momentum
Abbott, Bristol-Myers, Celgene, Eli Lilly, Novartis, Roche, Valeant… Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
